

Vitamin D serum levels in multiorgan failure critically ill patients undergoing continuous renal replacement therapies

Tomasz Czarnik¹, Aneta Czarnik², Ryszard Gawda¹, Maciej Piwoda³, Maciej Marszałski³, Mirosław Czuczwar⁴

¹Department of Anaesthesiology, Intensive Care, and Regional ECMO Centre, Institute of Medical Sciences, University of Opole, Poland

²Department of Endocrinology, Voivodeship Hospital in Opole, Poland

³Department of Anaesthesiology, Intensive Care, and Regional ECMO Centre, Opole University Hospital, Poland

⁴2nd Department of Anaesthesiology and Critical Care, Medical University of Lublin, Poland

Abstract

Introduction: Severe vitamin D deficiency in critically ill patients is linked to mortality. There are no scientific data regarding vitamin D status in critically ill patients undergoing continuous renal replacement therapies.

Methods: We aimed to measure vitamin D serum levels in critically ill patients with multiorgan failure undergoing continuous renal replacement therapies. Vitamin D serum measurements in 12-hour time intervals were performed in 20 patients undergoing continuous renal replacement therapies through continuous veno-venous haemodiafiltration (the study group). The results were then compared with the historical control group (20 patients without renal replacement therapy).

Results: In the control group the median vitamin D level initially decreased, then stabilised around the fourth and fifth measurement, after which it appeared to increase unevenly. In the study group the median vitamin D level decreased considerably, and then stabilised around the third measurement. Although the differences between groups gradually increased for the last three measurements, there was insufficient evidence to indicate that they were statistically significant ($P > 0.05$). Significant correlations were found between the time of measurement and the level of vitamin D in the study ($R = -0.31$, $P = 0.0002$) and control groups ($R = -0.18$, $P = 0.0341$).

Conclusions: Vitamin D serum levels decline rapidly during the course of critical illness in patients undergoing continuous renal replacement therapies. No statistically significant differences in the levels of vitamin D between the study and control groups were found.

Key words: vitamin D, intensive care, acute kidney injury, continuous renal replacement therapy, critical illness.

Anestezjologia Intensywna Terapia
2020; 52, 5: 363–369

Otrzymano: 26.06.2020,
zaakceptowano: 06.08.2020

ADRES DO KORESPONDENCJI:

Tomasz Czarnik, Anaesthesiology, Intensive Care, Regional ECMO Centre, Institute of Medical Sciences, University of Opole, Aleja Witosa 26, 45-401 Opole, Poland, e-mail: tczarnik@mac.com

Vitamin D is recognised as having two main functions in humans. In the classic function, vitamin D is responsible for extracellular calcium metabolism, namely intestinal absorption and musculoskeletal milieu homeostasis [1–3]. In the pleiotropic (non-skeletal) function, it resembles a hormonal mechanism of action. Vitamin D binds to genomic sequences, known as vitamin D response elements, that are scattered in the body, and subsequently regulates gene expression. Specific vitamin D receptors are omnipresent in most human tissues. Vitamin D response elements are capable of subsequently modifying cellular processes such as proliferation, differentiation, apoptosis, angiogenesis, hor-

mone secretion, and membrane stabilisation [3–9]. The above-mentioned modifications potentially influence physiological interactions such as anti-inflammatory processes, blood pressure regulation, glycaemic control, as well as the modification of innate and adaptive immunity [1, 3–9].

Vitamin D deficiency is very common in critically ill patients [9]. Severe deficiency is a risk factor for acute respiratory distress syndrome, acute kidney injury, multiorgan failure, and morbidity in critically ill septic shock patients [9–17].

The characteristic deficiency and decline in vitamin D serum concentrations shortly after admission have been observed in intensive care patients [9, 17].

Several studies have reported a relationship in critically ill patients between severe deficiency and mortality and length of ICU stay [12, 18–28]. However, most of these trials were retrospective, and the vitamin D kinetics was not measured. Although vitamin D deficiency is a potentially modifiable factor that can be corrected by intensive oral supplementation in the ICU [29], surprisingly there are only a few prospective observational or interventional clinical trials studying vitamin D serum concentration changes over time [9, 17, 26, 30–36]. Moreover, there are no scientific data regarding vitamin D serum concentration changes in multiorgan failure critically ill patients undergoing continuous renal replacement therapies.

The primary objective of this study was to assess the vitamin D serum levels in multiorgan failure critically ill patients undergoing regional citrate anticoagulation continuous renal replacement therapies (study group) by performing periodic serum vitamin D measurements in short time intervals. The second objective was to compare the data obtained with the general intensive care population (control group, no renal replacement therapy group). We hypothesised that critically ill patients undergoing continuous renal replacement therapies are particularly prone to severe vitamin D deficiency during the course of critical illness.

METHODS

This was a prospective observational cohort study conducted from September 2015 to November 2018 in a single, 11-bed, mixed ICU. Written informed consent was obtained from the patients' relatives. The study was approved by the Regional Ethics Committee (protocol number: 214/2015; date of approval: 25/03/2015), registered before the recruitment of participants (clinicaltrials.gov; Identifier: NCT02414386) and carried out according to the principles of the Declaration of Helsinki. The vitamin D serum concentration changes in a general population of intensive care patients (control group) were presented in our previous publication and used here as the historical control [9].

Control group

We included consecutive critically ill patients with vitamin D levels above 10 ng mL⁻¹ at admission and with respiratory and circulatory failure. We defined respiratory failure as the need for invasive mechanical ventilation, and we defined circulatory failure as the need for inotrope and/or vasopressor administration [9].

Patients who met any of the following criteria were excluded: acute liver failure, acute kidney injury treated with renal replacement therapy, hyper-

calcaemia at admission (total calcium plasma level > 10.6 mg dL⁻¹, total ionised calcium plasma level > 1.35 mmol L⁻¹), parathyroid gland disease at admission, serum vitamin D level < 10 ng mL⁻¹ at admission, end-stage renal disease, admission from another ICU or readmission, age under 18 years, or lack of consent from relatives. We established a cut-off value for serum vitamin D level of 10 ng mL⁻¹ as extremely low. We assumed that below this level, vitamin D status assessment was pointless [9].

Study group

We included critically ill patients with vitamin D levels above 10 ng mL⁻¹ at admission, with respiratory and circulatory failure and acute kidney injury treated with continuous renal replacement therapy by continuous veno-venous haemodiafiltration (CVVHDF), which was started no later than 48 hours after admission. CVVHDF was performed in each patient using regional citrate anticoagulation, Prismaflex system, and an ST150 set (Prismaflex, Gambro Lundia AB, Lund, Sweden). The CVVHDF dose was set between 30 and 40 mL kg⁻¹ h⁻¹.

Patients who met any of the following criteria were excluded: acute liver failure, hypercalcaemia at admission (total calcium plasma level > 10.6 mg dL⁻¹, total ionised calcium plasma level > 1.35 mmol L⁻¹), parathyroid gland disease at admission, serum vitamin D level < 10 ng mL⁻¹ at admission, end-stage renal disease, admission or readmission from another ICU, age under 18 years, or lack of consent from relatives. As in the control group, we established a cut-off value for serum vitamin D level of 10 ng mL⁻¹ as extremely low.

Vitamin D (25-hydroxy-vitamin D) was measured in exactly the same way for both groups. Blood samples were taken from an arterial line or central venous line, or by direct peripheral venous puncture, and were collected in ethylenediaminetetraacetic acid (EDTA) tubes. Blood samples were protected from exposure to light, transported to the hospital laboratory within 30 minutes, centrifuged at 3500 rpm for 10 minutes, and processed by laboratory technicians. The vitamin D serum level was measured using an electrochemiluminescence binding assay on Cobas e411 or Cobas 6000 immunoassay analysers (Roche Diagnostics GmbH, Mannheim, Germany). The coefficient of variation (the amount of variability relative to the mean) of the method was estimated to be 0.8–5.8%.

Consecutive patients admitted to the ICU were assessed in terms of study participation (inclusion and exclusion criteria). In the majority of patients, the first vitamin D serum level was measured at the time of admission to the ICU. If the first vitamin D serum level was higher than 10 ng mL⁻¹, the patient was included in the study. The first vitamin D mea-

measurements in the study group were performed before starting renal replacement therapies. The next set of vitamin D serum levels were taken in 12-hour time intervals (twice daily, at 6 a.m. and 6 p.m.). The minimum number of vitamin D measurements was four and the maximum was eight per patient [9].

All demographic data (date, name, hospital documentation number, sex, age, diagnosis at admission, comorbidities, Sequential Organ Failure Assessment Score [SOFA], and additional laboratory tests) were recorded in the hospital's electronic database. After the recruitment process, patient data were extracted from the electronic database, the patient's identification was blinded, and the data were transferred to the statistician for analysis [9].

Statistical methods

The quantitative variables were characterised by the arithmetic mean of standard deviation, median, and max/min (range). The qualitative variables were presented with the use of count and percentage. In order to check whether a quantitative variable derived from a population with a normal distribution, the *W* Shapiro-Wilk test was used. To prove the hypotheses on homogeneity of variances, the Leven (Brown-Forsythe) test was used. Statistical significance of differences between the two groups was tested with Student's *t*-test or *U* Mann-Whitney test. The significance of differences between more than two groups was assessed with the *F* test. In the case of statistically significant differences between two groups, post hoc tests were used (Tukey test for *F* or Dunn for Friedman). χ^2 tests for independence were used for qualitative variables. In order to determine dependence, strength, and direction between variables, correlation analysis was used by determining the Pearson or Spearman correlation coefficients. In all the calculations a statistical significance level of $\alpha = 0.05$ was used. Statistical analyses were performed using TIBCO (Software Inc., 2017), Statistica v. 13 (Palo Alto, CA, USA, 2017, <http://statistica.io>), and Excel.

RESULTS

A total of 1166 patients were evaluated for participation in the study. Reasons for exclusion in the control group were the following: no coexisting circulatory and respiratory failure, vitamin D measurement not performed, end-stage renal disease, vitamin D serum level below 10 ng mL⁻¹, acute kidney injury treated with renal replacement therapy, admission from another ICU or readmission, acute liver failure, and age under 18 years [9]. Reasons for exclusion in the study group were the following: no coexisting circulatory, respiratory failure and acute kidney injury treated with CVVHDF, vitamin D measurement not performed, end-stage renal disease,

TABLE 1. Descriptive statistics of patients

Parameter	Study group (n = 20)	Control group (n = 20)	P-value
Age (years)			
Mean (SD)	67.2	64.2	0.7785 ¹
Range (min–max)	27–84	47–84	
Median	68	64	
SOFA at admission			
Mean (SD)	11.6	12.9	0.0179 ²
Range (min–max)	7–18	8–16	
Median	11	12.5	
Primary diagnosis at admission, n (%)			
Cardiac arrest	9 (45.0)	10 (50.0)	0.7515 ³
Multiorgan failure	5 (25.0)	0 (0.0)	0.0168 ³
Septic shock	3 (15.0)	1 (5.0)	0.2918 ³
Multi trauma	2 (10.0)	1 (5.0)	0.5483 ³
Cardiogenic shock	1 (5.0)	3 (15.0)	0.2918 ³
Respiratory failure	0 (0.0)	5 (25.0)	0.0168 ³

¹Student's *t*-test, ²Mann-Whitney *U* test, ³ χ^2 test

vitamin D serum level below 10 ng mL⁻¹, admission from another ICU or readmission, acute liver failure, and age under 18 years. Finally, 40 patients met the inclusion criteria, 20 patients were included in the control group, and 20 patients were included in the study group. The baseline demographics for both groups are shown in Table 1.

Control group

Figure 1 shows the distribution of vitamin D levels in the control group. The median vitamin D level decreased until the fourth measurement. This level stabilised around the fourth and fifth measurement, and then increased unevenly. In a sizable majority of time points, the distributions were skewed. The vari-




FIGURE 1. The distribution of the level of vitamin D in the control group (*statistically significant differences)

ability in observations was not constant over time, and there was no apparent trend [9].

The vector of fixed effect coefficients determines the shape of the curve that describes changes in the level of vitamin D for an average patient. For the first measurement, the average level was 18.57 ng L⁻¹. This value changed over time, which is summarised by another two coefficients. Rather than considering a discrete rate of change in time, instead the change in the average level of vitamin D per small change of time could be investigated. This change can be derived by calculating the first derivative, which yields a linear function of time, i.e. $-2.49 + 0.61 t$. Substituting the time with the consecutive values (the first measurement at $t = 0$), the following change rates are obtained: $-2.49, -1.88, -1.27, -0.66, -0.05, 0.56, 1.17$, and 1.78 . It is clear that the greatest decrease in the level of vitamin D was at the beginning. Subsequently, there was a minor decline, which could be considered a stabilisation; then, the final phase reflects a slight increase [9].

The analysis also demonstrates the importance of the patient effect, which is significant not only in terms of the average level of vitamin D but also the rate of change. This significance means that each patient's intercept differs from the average value of 18.57 ng L⁻¹ by the random effect of 7 ng L⁻¹. There was a clear shift from an average-level curve to a patient-level curve. This variability is attributed to a different initial level of vitamin D. Similarly, each patient's slope (rate of change) differed from the average value of -2.49 ng L⁻¹ due to the random effect of 0.72 ng L⁻¹ [9].

Study group

Figure 2 shows the distribution of the vitamin D level in the study group. Initially, the median vitamin D level decreased considerably and then stabilised around the third measurement. Unlike the control group, there was no subsequent increase.




FIGURE 2. The distribution of the level of vitamin D in the study group (*statistically significant differences)

At most of the time points, the distributions were also skewed. The variability in observations was not constant over time, and there was no apparent trend.

The vector of fixed effect coefficients determines the shape of the curve that describes changes in the level of vitamin D for an average patient. For the first measurement, the average level was approximately 20 ng L⁻¹. This value changed over time, which is summarised by another two coefficients. Rather than considering a discrete rate of change in time, the change in the average level of vitamin D per small change of time could be investigated. This change can be derived by calculating the first derivative, which yields a linear function of time, i.e. $-8.45 t^2$. Substituting the time for the consecutive values, the following change rates are obtained: $-8.45, -2.11, -0.94, -0.53, -0.34, -0.23, -0.17$, and -0.13 . The greatest drop in the level of vitamin D was at the very beginning. Subsequently, there was a minor decline and, finally, a stabilisation.

The analysis also highlights the patient effect, which was significant not only in terms of the average level of vitamin D but also the rate of change. This finding means that each patient's intercept differs from the average value of 20 ng L⁻¹ by the random effect of 5.45 ng L⁻¹. There was a shift from an average-level curve to a patient-level curve. This variability can be attributed to a different initial level of vitamin D. Similarly, each patient's slope (rate of change) differs from the average value of -8.45 ng L⁻¹ by the random effect of 7.43 ng L⁻¹ at admission and 0.93 ng L⁻¹ at the last measurement. Thus, the patient effect rapidly diminishes over time.

Comparative statistics

Table 2 shows the mean vitamin D levels for all measurements for both groups. There were no significant differences between the groups with respect to the level of vitamin D ($P > 0.05$). To compare both groups, analysis of mean values of the vitamin D levels in the study and control groups are depicted in Figure 3. Statistically significant correlations were found between the time of measurement and the level of vitamin D in the study (correlation coefficient $R = -0.31, P = 0.0002$) and control groups (correlation coefficient $R = -0.18, P = 0.0341$) (Figure 4). There were no significant differences between the groups with respect to correlation coefficient ($P = 0.6886$). Although the differences between groups gradually increased for the last three measurements, there was insufficient evidence to indicate that they were statistically significant.

DISCUSSION

A serum vitamin D concentration of less than 20 ng mL⁻¹ is defined as a deficiency, a level between

TABLE 2. Tabular summary of mean/median values of the level of vitamin D in groups: study and control (mean, SD – standard deviation, minimum, maximum, and median)

Parameter	Study group (n = 20)	Control group (n = 20)	P-value
Measurement 1			
Mean (SD)	20.0 (8.0)	18.7 (7.0)	0.5885 ¹
Range (min–max)	11.0–44.5	10.6–39.0	
Median	18.9a	17.9	
Measurement 2			
Mean (SD)	16.1 (5.4)	16.3 (8.5)	0.9052 ²
Range (min–max)	9.0–30.0	3.4–35.0	
Median	15.4	16.2	
Measurement 3			
Mean (SD)	14.3 (5.4)	14.6 (7.6)	0.8839 ²
Range (min–max)	4.9–27.7	3.2–32.5	
Median	12.8	14.1	
Measurement 4			
Mean (SD)	13.2 (5.4)	13.9 (8.1)	0.8924 ¹
Range (min–max)	6.1–26.8	5.0–38.5	
Median	12.7	11.3	
Measurement 5			
Mean (SD)	13.2 (5.7)	13.6 (9.4)	0.6578 ¹
Range (min–max)	5.7–29.0	4.6–42.5	
Median	13.2	10.8	
Measurement 6			
Mean (SD)	13.2 (5.1)	14.8 (10.2)	0.9503 ¹
Range (min–max)	5.9–25.6	4.3–42.8	
Median	12.9	13.0	
Measurement 7			
Mean (SD)	12.9 (5.7)	16.3 (9.7)	0.5441 ¹
Range (min–max)	5.1–27.0	6.6–40.0	
Median	13.0	12.1	
Measurement 8			
Mean (SD)	12.7 (5.4)	15.3 (8.8)	0.9692 ¹
Range (min–max)	4.1–24.0	8.8–31.9	
Median	12.9	11.6	

¹Mann-Whitney U test, ²Student's t-test

20 and 30 ng mL⁻¹ as an insufficiency, and a serum concentration of more than 30 ng mL⁻¹ as a normal vitamin D level [7, 9, 37]. For our study, we defined severe deficiency as less than 10 ng mL⁻¹. Our results reveal that critically ill patients are especially prone to initial severe vitamin D deficiency, and critical illness escalates this phenomenon.

We performed 200 initial vitamin D measurements during the study period (as part of the assessment for eligibility), 130 (65%) of which had serum vitamin D concentrations below 10 ng mL⁻¹. We assume that the real severe deficiency rate could




FIGURE 3. Comparative analysis of mean values of the level of vitamin D in groups: study and control. There were no significant differences between the groups with respect to the level of vitamin D value




FIGURE 4. Correlation between vitamin D level and time of measurement in study and control groups

be even higher because for most patients excluded from the study, we did not perform measurements. A severe vitamin D deficiency is common in critically ill patients (estimated prevalence of 40–99%); however, the mechanism responsible has not been definitively identified [9, 18, 38, 39].

In our study, summary statistics of the vitamin D status in both groups revealed that the vitamin D serum levels were unstable during critical illness. The potential mechanisms responsible for this finding may be as follows: the serum vitamin D status mirrors the severity of illness, i.e. a hypoalbuminaemia, which is a typical feature of critical illness; low serum concentration of vitamin D binding protein during the course of critical illness; decreased synthesis of vitamin D binding protein; renal wasting of vitamin D; interstitial extravasation caused by increased vascular permeability; lack of sun exposure in the ICU; malnutrition; decreased renal production of 1,25(OH)D₃; and increased tissue conversion of 25(OH)D₃ to 1,25(OH)D₃ [1, 9, 29].

In the control group, we observed a rapid decrease in vitamin D levels followed by stabilisation and then a small increase. We hypothesise that the observed trend could be consistent with the effect of therapy introduced after the patient's admission to the ICU (clinical instability before treatment then stabilisation and improvement after the treatment implementation).

In the study group, the initial trends were similar to the control group, and stabilisation occurred around the third measurement. However, unlike the control group, there was no subsequent increase. We also hypothesise that the lack of a subsequent increase in the study group could have been influenced by CVVHDF (washout during convection process) or could be related to the fact that multiorgan failure patients with acute kidney injury are generally sicker and have an increased risk of mortality compared to patients without AKI.

Poor vitamin D status in critically ill patients raises the question of whether early and rapid supplementation in the initial phase of a critical illness could influence the outcome measures. In a randomised study, which assessed the effect of two doses of intramuscular cholecalciferol on serial serum vitamin D levels, Nair *et al.* found that correction of a vitamin D deficiency is possible in critically ill patients, but no statistically significant difference in mortality and hospital length of stay was observed [35]. In a randomised, placebo-controlled trial, Quraishi *et al.* investigated the changes in vitamin D status in septic ICU patients who were treated with a placebo versus cholecalciferol. They found that supplementation raises vitamin D serum concentrations in patients with sepsis and septic shock [34]. In the VITdAL-ICU study, Amrein *et al.* reported that the administration of a high oral dose of vitamin D versus placebo did not reduce the hospital length of stay, hospital mortality, and six-month mortality in the study group. However, the subgroup analysis revealed a trend towards lower hospital mortality in the severe vitamin D deficiency subgroup of patients in whom supplementation was performed [32].

A multicentre, randomised, placebo-controlled trial (VIOLET-NCT03096314) studying an early high-dose vitamin D supplementation in the critically ill revealed no apparent benefit [40]. The authors of the trial established a cut-off value of 20 ng mL⁻¹ for vitamin D supplementation. However, it is known from the VITdAL-ICU study that a trend towards lower hospital mortality was observed when supplementation was performed exclusively in the severe vitamin D deficiency subgroup of patients (the cut-off value of less than 12 ng mL⁻¹) [32].

Finally, another large, multicentre, randomised, placebo-controlled study (VITDALIZE-NCT03188796) investigating the relationship between intensive

oral vitamin D supplementation and outcome in critically ill patients is underway. The recent European Society for Clinical Nutrition and Metabolism guidelines on clinical nutrition in the intensive care unit recommends a single high oral dose of 500,000 UL vitamin D within one week of admission in critically ill patients with vitamin D plasma levels below 12.5 ng mL⁻¹ [29]. We still do not know if the recommended dose of 500,000 UL is suitable for multiorgan failure critically ill patients undergoing continuous renal replacement therapies. Based on the results of our study, a higher dose would probably be optimal in this group of patients.

Our study has three main limitations. The first is the small number of patients included. As previously mentioned, we established a cut-off value for serum vitamin D of more than 10 ng mL⁻¹ as the inclusion criterion. We assumed that below this level, a vitamin D serum levels assessment was pointless. Given that severe hypovitaminosis D is very common in intensive care units, only 40 patients out of 1166 assessed for eligibility were included because of the strict inclusion criteria. The second limitation is the observational nature of the trial. A randomised trial studying the relationship between a high-dose oral vitamin D supplementation regimen in multiorgan failure critically ill patients undergoing continuous renal replacement therapies and outcome would be more informative. Finally, the study population was rather heterogeneous. However, our patients represent a typical intensive care milieu.

CONCLUSIONS

Multiorgan failure critically ill patients undergoing continuous renal replacement therapies are highly prone to severe vitamin D deficiency. We found that the vitamin D serum concentration decreases rapidly during the course of critical illness in these patients. However, we did not observe statistically significant differences between the renal replacement therapy group (study group) and general intensive care group (control group) with respect to the level of vitamin D ($P > 0.05$). Nonetheless, the differences between groups gradually increased for the last three measurements showing the probable general trend.

ACKNOWLEDGEMENTS

1. Financial support and sponsorship: none.
2. Conflicts of interest: none.

REFERENCES

1. Quraishi SA, Camargo CA. Vitamin D in acute stress and critical illness. *Curr Opin Clin Nutr Metab Care* 2012; 15: 625-634. doi: 10.1097/MCO.0b013e328358fc2b.
2. Bendik I, Friedel A, Roos FF, Weber P, Eggersdorfer M. Vitamin D: a critical and essential micronutrient for human health. *Front Physiol* 2014; 5: 248. doi: 10.3389/fphys.2014.00248.

3. Amrein K, Christopher KB, McNally JD. Understanding vitamin D deficiency in intensive care patients. *Intensive Care Med* 2015; 41: 1961-1964. doi: 10.1007/s00134-015-3937-4.
4. Lee P, Eisman JA, Center JR. Vitamin D deficiency in critically ill patients. *N Engl J Med* 2009; 360: 1912-1914. doi: 10.1056/NEJM0809996.
5. McKinney TJ, Patel JJ, Bennis MV, Nash NA, Miller KR. Vitamin D status and supplementation in the critically ill. *Curr Gastroenterol Rep* 2016; 18: 18. doi: 10.1007/s11894-016-0492-2.
6. Rosen CJ. Vitamin D insufficiency. *N Engl J Med* 2011; 364: 248-254. doi: 10.1056/NEJMcp1009570.
7. Holick MF. Vitamin D deficiency. *N Engl J Med* 2007; 357: 266-281. doi: 10.1056/NEJMra070553.
8. Paul G, Brehm JM, Alcom JF, Holguin F, Aujla SJ, Celedon JC. Vitamin D and asthma. *Am J Respir Crit Care Med* 2012; 185: 124-132. doi: 10.1164/rccm.201108-1502CI.
9. Czarnik T, Czarnik A, Gawda R, et al. Vitamin D kinetics in the acute phase of critical illness: a prospective observational study. *J Crit Care* 2018; 43: 294-299. doi: 10.1016/j.jcrr.2017.09.179.
10. Rech MA, Hunsaker T, Rodriguez J. Deficiency in 25-hydroxyvitamin D and 30-day mortality in patients with severe sepsis and septic shock. *Am J Crit Care* 2014; 23: 72-79. doi: 10.4037/ajcc2014723.
11. Moromizato T, Litonjua AA, Braun AB, et al. Association of low serum 25-hydroxyvitamin D levels and sepsis in the critically ill. *Crit Care Med* 2014; 42: 97-107. doi: 10.1097/CCM.0b013e31829eb7af.
12. de Haan K, Groeneveld AB, de Geus HR, Egal M, Struijs A. Vitamin D deficiency as a risk factor for infection, sepsis and mortality in the critically ill: systematic review and meta-analysis. *Crit Care* 2014; 18: 660. doi: 10.1186/s13054-014-0660-4.
13. Kempker JA, Tangpricha V, Ziegler TR, Martin GS. Vitamin D in sepsis: from basic science to clinical impact. *Crit Care* 2012; 16: 316. doi: 10.1186/cc11252.
14. De Pascale G, Vallecocchia MS, Schiattarella A, et al. Clinical and microbiological outcome in septic patients with extremely low 25-hydroxyvitamin D level at initiation of critical care. *Clin Microbiol Infect* 2016; 22: 456. doi: 10.1016/j.cmi.2015.12.015.
15. Upala S, Sanguankeo A, Permpalung N. Significant association between vitamin D deficiency and sepsis: a systematic review and meta-analysis. *BMC Anesthesiol* 2015; 15: 84. doi: 10.1186/s12871-015-0063-3.
16. Parekh D, Patel JM, Scott A, et al. Vitamin D deficiency in human and murine sepsis. *Crit Care Med* 2017; 45: 282-289. doi: 10.1097/CCM.0000000000002095.
17. Ostermann M, Summers J, Lei K, et al. Micronutrients in critically ill patients with severe acute kidney injury – a prospective study. *Sci Rep* 2020; 10: 1505. doi: 10.1038/s41598-020-58115-2.
18. Leaf DE, Croy HE, Abrahams SJ, Raed A, Waikar SS. Cathelicidin antimicrobial protein, vitamin D, and risk of death in critically ill patients. *Crit Care* 2015; 19: 80. doi: 10.1186/s13054-015-0812-1.
19. Amrein K, Papinutti A, Mathew E, Vila G, Parekh D. Vitamin D and critical illness: what endocrinology can learn from intensive care and vice versa. *Endocr Connect* 2018; 7: R304-315. doi: 10.1530/EC-18-0184.
20. Amrein K, Quraishi SA, Litonjua AA, et al. Evidence for a U-shaped relationship between prehospital vitamin D status and mortality: a cohort study. *J Clin Endocrinol Metab* 2014; 99: 1461-1469. doi: 10.1210/jc.2013-3481.
21. Quraishi SA, Bittner EA, Blum L, et al. Prospective study of vitamin D status at initiation of care in critically ill surgical patients and risk of 90-day mortality. *Crit Care Med* 2014; 42: 1365-1371. doi: 10.1097/CCM.0000000000000210.
22. Braun A, Chang D, Mahadevappa K, et al. Association of low serum 25-hydroxyvitamin D levels and mortality in the critically ill. *Crit Care Med* 2011; 39: 671-677. doi: 10.1097/CCM.0b013e318206ccdf.
23. Amrein K, Litonjua AA, Moromizato T, et al. Increases in pre-hospital serum 25(OH)D concentrations are associated with improved 30-day mortality after hospital admission: a cohort study. *Clin Nutr* 2016; 35: 514-521.
24. Braun AB, Gibbons FK, Litonjua AA, Giovannucci E, Christopher KB. Low serum 25-hydroxyvitamin D at critical care initiation is associated with increased mortality. *Crit Care Med* 2012; 40: 63-72. doi: 10.1097/CCM.0b013e31822d74f3.
25. Venkatram S, Chilimuri S, Adrish M, et al. Vitamin d deficiency is associated with mortality in the medical intensive care unit. *Crit Care* 2011; 15: R292. doi: 10.1186/cc10585.
26. Moraes RB, Friedman G, Wawrzyniak IC, et al. Vitamin D deficiency is independently associated with mortality among critically ill patients. *Clinics (Sao Paulo)* 2015; 70: 326-332. doi: 10.6061/clinics/2015(05)04.
27. Amrein K, Zajic P, Schnedl C, et al. Vitamin D status and its association with season, hospital and sepsis mortality in critical illness. *Crit Care* 2014; 18: R47. doi: 10.1186/cc13790.
28. Matthews LR, Ahmed Y, Wilson KL, Griggs DE, Danner OK. Worsening severity of vitamin D deficiency is associated with increased length of stay, surgical intensive care unit cost, and mortality rate in surgical intensive care unit patients. *Am J Surg* 2012; 204: 37-43. doi: 10.1016/j.amjsurg.2011.07.021.
29. Singer P, Blaser AR, Berger MM, et al. ESPEN guideline on clinical nutrition in the intensive care unit. *Clin Nutr* 2019; 38: 48-79.
30. Nair P, Lee P, Reynolds C, et al. Significant perturbation of vitamin D-parathyroid-calcium axis and adverse clinical outcomes in critically ill patients. *Intensive Care Med* 2013; 39: 267-274. doi: 10.1007/s00134-012-2713-y.
31. Krishnan A, Ochola J, Mundy J, et al. Acute fluid shifts influence the assessment of serum vitamin D status in critically ill patients. *Crit Care* 2010; 14: R216. doi: 10.1186/cc9341.
32. Amrein K, Schnedl C, Holl A, et al. Effect of high-dose vitamin D3 on hospital length of stay in critically ill patients with vitamin D deficiency: the VITdAL-ICU randomized clinical trial. *JAMA* 2014; 312: 1520-1530. doi: 10.1001/jama.2014.13204.
33. Venkatesh B, Davidson B, Robinson K, et al. Do random estimations of vitamin D3 parathyroid hormone reflect the 24-h profile in the critically ill? *Intensive Care Med* 2012; 38: 177-179.
34. Quraishi SA, De Pascale G, Needleman JS, et al. Effect of cholecalciferol supplementation on vitamin D status and cathelicidin levels in sepsis: a randomized, placebo-controlled trial. *Crit Care Med* 2015; 43: 1928-1937. doi: 10.1097/CCM.0000000000001148.
35. Nair P, Venkatesh B, Lee P, et al. A randomized study of a single dose of intramuscular cholecalciferol in critically ill adults. *Crit Care Med* 2015; 43: 2313-2320. doi: 10.1097/CCM.0000000000001201.
36. Ney J, Heyland DK, Amrein K, et al. The relevance of 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D concentration for postoperative infections and postoperative organ dysfunctions in cardiac surgery patients: The eVIDenCe study. *Clin Nutr* 2019; 38: 2756-2762. doi: 10.1016/j.clnu.2018.11.033.
37. Venkatesh B, Nair P. Hypovitaminosis D and morbidity in critical illness: is there proof beyond reasonable doubt? *Crit Care* 2014; 18: 138. doi: 10.1186/cc13863.
38. Ross AC, Manson JE, Abrams SA, et al. The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. *J Clin Endocrinol Metab* 2011; 96: 53-58. doi: 10.1210/jc.2010-2704.
39. Brook K, Camargo CA, Christopher KB, Quraishi SA. Admission vitamin D status is associated with discharge destination in critically ill surgical patients. *Ann Intensive Care* 2015; 5: 23. doi: 10.1186/s13613-015-0065-9.
40. The National Heart, Lung, and Blood Institute PETAL Clinical Trials Network. Early high-dose vitamin D3 for critically ill, vitamin D – deficient patients. *N Engl J Med* 2019; 381: 2529-2540. doi: 10.1056/NEJMoa1911124.